pharmaphorum
JULY 21, 2022
The appointment might raise some eyebrows given Roche’s need to drive pharma sales as it copes with the loss of patent protection on an earlier generation of antibody-based therapies – now being hit by biosimilar competition – but Schwan is confident Schinecker is the right man to lead the company forward.
pharmaphorum
JANUARY 19, 2023
GIRFT and competition He went on: “Improvement needs competition – everything else is a proxy; it doesn’t work well. When Milburn and Blair introduced competition in 2004-2008 it did start to make a difference.” Since 2008, the budget for NHS has grown 1% and the market 4%. Highly unlikely.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JANUARY 4, 2023
In an update on the litigation posted this morning, Astellas confirmed that the Court of Appeals for the Federal Circuit (CAFC) had upheld a lower court ruling that Hospira’s generic does not infringe any of the patents that are protecting Lexiscan (regadenoson injection) from competition.
The Brooks Group
OCTOBER 14, 2019
Companies who proactively recognized the threat ahead of the 2008 recession achieved six percentage points better Total Shareholder Return in the downturn than companies that did not address the challenge early. The ultimate competitive advantage is your team’s selling skills. Take a Long-Term Perspective. Click below to discover how.
pharmaphorum
JULY 15, 2022
Things became litigious in 2017, when a Delaware court found that Teva’s label for its generic encouraged doctors to use the drug to treat heart failure in a way that infringed GSK’s RE40,000 patent, which was reissued by the Patent and Trademark Office (PTO) in 2008.
Salesforce
MARCH 3, 2022
After the accident in 2008, Schultz was anxious to get back into sports, but struggled to find prosthetics to support extreme movement. Tuning the equipment, even the smallest bit, is crucial when fractions of second matter in competition. Turning data into insights: how activity data replaces trial and error. Learn more.
Pharmaceutical Technology
SEPTEMBER 22, 2022
AstraZeneca ’s cholesterol drug Crestor (rosuvastatin) was approved in 2003 in the US but only approved in Germany in 2008. The company now faces a highly competitive generics market for its lead drug. Amarin’s net product revenue was $577.9 million in 2021 and $607 million in 2020, as per its financial filings.
Expert insights. Personalized for you.
109 
Let's personalize your content